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Abstract
Background: Exposures to toxic metals and deficiencies in essential metals disrupt placentation and may contribute
to preeclampsia. However, effects of exposure to combinations of metals remain unknown.
Objective: We investigated the relationship between urinary trace metals, circulating angiogenic biomarkers,
and preeclampsia using the LIFECODES birth cohort.
Methods: Urine samples collected during pregnancy were analyzed for 17 trace metals and plasma samples
were analyzed for soluble fms-like tyrosine-1 (sFlt-1) and placental growth factor (PlGF). Cox proportional hazard
models were used to estimate the hazard ratios (HR) of preeclampsia associated with urinary trace metals. Linear
regression models were used to estimate the relationship between urinary trace metals and angiogenic biomarkers.
Principal components analysis (PCA) was used to identify groups of metals and interactions between principal
components (PCs) loaded by toxic and essential metals were examined.
Results: In single-contaminant models, several toxic and essential metals were associated with lower PlGF and
higher sFlt-1/PlGF ratio. Detection of urinary chromium was associated with preeclampsia: HR (95% Confidence Interval
[CI]) = 3.48 (1.02, 11.8) and an IQR-increase in urinary selenium was associated with reduced risk of preeclampsia (HR: 0.28,
95% CI: 0.08, 0.94). Using PCA, 3 PCs were identified, characterized by essential metals (PC1), toxic metals (PC2),
and seafood-associated metals (PC3). PC1 and PC2 were associated with lower PlGF levels, but not
preeclampsia risk in the overall cohort.
Conclusions: Trace urinary metals may be associated with adverse profiles of angiogenic biomarkers and preeclampsia.
Keywords: Prenatal exposure, Metals, Metals mixtures, Angiogenic biomarkers, Preeclampsia
Background
Preeclampsia is a reproductive disorder that is diagnosed
by de novo hypertension and proteinuria after 20 weeks
gestation [1]. In the United States, the incidence of pre-
eclampsia has increased over the past several decades and
is estimated to affect approximately 5% of all pregnancies
[2, 3]. Importantly, the underlying etiology of preeclamp-
sia remains unknown. The origins of preeclampsia are
hypothesized to lie within the placenta. Preeclamptic
pregnancies are characterized by a placenta with shallow
invasion into the maternal decidua and incomplete re-
modeling of maternal spiral arteries [3]. As a consequence,
the preeclamptic placenta is poorly perfused and hypoxic,
giving rise to the systemic maternal endothelial dysfunc-
tion that characterizes the disorder [3, 4].
Given that preeclampsia is characterized by impaired
spiral artery remodeling, angiogenic biomarkers may
serve as predictors of preeclampsia risk [5, 6]. These
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: kelly.ferguson2@nih.gov
2Epidemiology Branch, Division of Intramural Research, National Institute of
Environmental Health Sciences, 111 T. W. Alexander Drive, Research Triangle
Park, NC 27709, USA
3Department of Environmental Health Sciences, University of Michigan
School of Public Health, Ann Arbor, MI 48109, USA
Full list of author information is available at the end of the article
Bommarito et al. Environmental Health           (2019) 18:63 
https://doi.org/10.1186/s12940-019-0503-5
biomarkers include soluble fms-like tyrosine kinase-1
(sFlt-1) and placental growth factor (PlGF). Both sFlt-1
and PlGF are members of the vascular endothelial growth
factor (VEGF) family and play important roles in adapting
maternal spiral arteries during placentation. More speci-
fically, higher levels of maternal circulating sFlt-1 indicate
anti-angiogenic activity, while lower levels of circulating
PlGF reflect reduced placental vascularization [7]. Both
biomarkers have been shown to predict preeclampsia [8].
In addition, the sFlt-1/PlGF ratio (i.e., a ratio of anti-
angiogenic to angiogenic activity) may more accurately
predict preeclampsia than either biomarker alone [9].
Prenatal environmental metals exposure may contri-
bute to preeclampsia risk. Previous studies have reported
associations between toxic metals, such as cadmium
(Cd) and lead (Pb), and an increased risk of preeclamp-
sia [10–15]. Alternatively, higher exposure to essential
metals, such as selenium (Se) and zinc (Zn), within a
recommended range, have been routinely associated
with a decreased risk of preeclampsia [16, 17]. Possible
mechanisms for these associations include that toxic
metals may impair trophoblast invasiveness [18–21],
generate placental oxidative stress [22], or lead to mater-
nal immunologic abnormalities [23], whereas essential
metals have antioxidant properties that may reduce the
effect of toxic exposures and promote normal placenta-
tion [24]. In addition, there are known toxicokinetic and
toxicodynamic interactions between toxic and essential
metals [25–27]. At an epidemiologic level, this has been
demonstrated with respect to both placental functioning
and preeclampsia, suggesting that essential metals may
mitigate the relationship between toxic metals and pre-
eclampsia [10, 28, 29].
While there is evidence for the role of metals in the
development of preeclampsia, many of these studies come
from populations with exceptionally high levels of toxic
metals exposure [11, 12, 14]. Evidence is more limited in
populations with lower exposures to toxic metals. In
addition, while studies have examined relationships be-
tween individual trace metals and preeclampsia, very few
studies have investigated metals in combination with one
another [11]. In the present study, we performed an
exploratory analysis of the relationship between 17 indi-
vidual trace metals, maternal circulating levels of angio-
genic biomarkers, and preeclampsia in the LIFECODES
birth cohort. In addition, we investigated the impact of
metals mixtures using principal components analysis
(PCA) to examine the relationship between groups of
urinary metals, preeclampsia, and levels of circulating
angiogenic biomarkers. We selected PCA, rather than
other statistical methods for analyzing chemical mixtures,
as a mixtures-based approach as a method of dimension
reduction and to examine groups of metals that may share
important exposure sources or toxicities. Lastly, potential
interactions between principal components characterized
by toxic and essential metals were also investigated.
Methods
Subject recruitment
LIFECODES is an ongoing prospective birth cohort that
began recruitment in 2006 at Brigham and Women’s Hos-
pital (BWH) in Boston, MA. The study has few exclusion
criteria. Specifically, women are eligible for enrollment
into the LIFECODES cohort if they are at least 18 years of
age, are seeking prenatal care before 15 weeks gestation,
and intend on delivery at BWH [30]. At the first visit (me-
dian, 10 weeks gestation), women completed detailed
questionnaires of demographic information and medical
history and provided informed consent. Gestational age
was defined according to the guidelines of the American
College of Obstetricians and Gynecologists (ACOG), with
the last menstrual period verified by first trimester ultra-
sound scanning [31]. Additional questionnaire data and
urine samples are collected at three subsequent study
visits (median, 18, 26, and 35 weeks gestation) and stored
at − 80 °C until analysis [32]. All research was approved by
the Institutional Review Board at BWH and was deemed
exempt by the University of Michigan and the National
Institute of Environmental Health Sciences (NIEHS).
The present analysis used subjects from a case-
control study of preterm birth recruited from 2006 to
2008, which is nested in the parent LIFECODES cohort
(Additional file 1: Figure S1). This case-control study
included almost all cases of singleton preterm birth
during this period and unmatched singleton controls
were included in a 1:3 ratio [33]. The primary purpose
of this case-control study was to examine the relation-
ship between prenatal environmental exposures and
preterm birth [34]. Participants in the case-control
study were included in this analysis if they had urine
samples from the 3rd study visit available for metals
analysis (n = 390). Importantly, demographic characte-
ristics in the subset of women with urine samples at the
3rd study visit is highly similar to both the larger case-
control study of preterm birth [34] and the overall
LIFECODES cohort [33]. To account for the dispropor-
tionate number of preterm births in our analysis, we
applied inverse probability weighting based on preterm
birth case status to all statistical analyses [35]. Thus,
results are generalizable to what would have been
observed in the parent LIFECODES birth cohort.
After delivery, preeclampsia diagnosis and diagnosis date
were abstracted from medical records. Preeclampsia was
defined according to ACOG guidelines between 2006 and
2008: elevated maternal blood pressure (> 140mmHg sys-
tolic and/or > 90mmHg diastolic) and proteinuria (> 300
mg/24 h or a protein/creatinine ratio > 0.20) after 20 weeks
gestation [1]. All cases of preeclampsia were verified by two
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maternal-fetal medicine specialists and diagnosis date was
used to determine the gestational age of preeclampsia on-
set. In the case of conflict, a third specialist reviewed the
case. Among the 390 participants, 28 women developed
preeclampsia. Among these 28 preeclampsia cases, one
woman developed preeclampsia postpartum. For the
present analysis, we excluded non-preeclamptics with ges-
tational hypertension (n = 7) to provide a cleaner compari-
son of women who developed preeclampsia against women
who did not develop any form of pregnancy-induced hyper-
tension, resulting in a final sample size of 383.
Urinary trace metals analysis
Urine samples from the 3rd study visit were sent to NSF
International (Ann Arbor, MI, USA) for trace metals
analysis, in collaboration with the Children’s Health Ex-
posure Analysis Research (CHEAR) Program. Trace
metals were analyzed using inductively coupled plasma-
mass spectrometry (ICP-MS), with methods described in
further detail elsewhere [32]. The metals analyzed in-
cluded arsenic (As), barium (Ba), beryllium (Be), Cd,
copper (Cu), chromium (Cr), mercury (Hg), manganese
(Mn), molybdenum (Mo), nickel (Ni), Pb, Se, tin (Sn),
thallium (Tl), uranium (U), tungsten (W), and Zn.
When metal concentrations were measured below the
limit of detection (LOD) by ICP-MS, the machine-read
values were used in analysis [32]. If the reported value
was below zero or blank, the value was replaced with
LOD/√2 [36, 37]. Metals with very low detection rates
(< 30%) were represented as detect versus non-detect in
all subsequent analyses.
Plasma biomarkers of angiogenesis
Measurement of circulating maternal sFlt-1 and PlGF
were measured in plasma samples collected at the 3rd
study visit [5, 38]. Both sFlt-1 and PlGF were measured
using ARCHITECT immunoassays (Abbot Laboratory,
Abbott Park, IL, USA). Specifically, unbound PlGF con-
centrations from 1 to 1500 pg/mL were measured and
total (unbound and bound) sFlt-1 concentrations from
0.10–150 ng/mL were measured. The ratio of sFlt-1 to
PlGF was also calculated for analysis [9]. The combined
intra- and interassay coefficients of variation were < 7%
for both PlGF and sFlt-1 [5].
Statistical analysis
First, differences in demographic and clinical character-
istics based on preeclampsia status were examined using
t-tests, chi-square tests, or Fisher’s exact tests, where ap-
propriate. Second, we analyzed trace metal distributions
by calculating median and interquartile ranges (IQR) by
preeclampsia status.
Third, the relationship between urinary trace metals
and the hazard ratio (HR) of preeclampsia were
estimated using Cox proportional hazard models. Both
unadjusted and adjusted Cox models were used to esti-
mate the relationship between an IQR increase in urin-
ary trace metals and the HR (95% Confidence Interval
[CI]) of preeclampsia. The proportional hazards assump-
tion was assessed by creating time-dependent variables
for each predictor in the model. Tests of these time-
dependent variables indicated that the proportional haz-
ards assumption was satisfied. Trace urinary metals were
log-transformed in order to improve model fit (i.e. lower
AIC). Crude models were created with adjustment for
gestational age at sample collection and, for metals that
were modeled continuously, urinary specific gravity
(SG). Potential confounders for adjusted analyses were
identified using a directed acyclic graph (DAG) and in-
cluded age (years), body mass index (BMI; kg/m2), ma-
ternal race (White/African American/Other), maternal
education (< high school/technical college/ junior or
some college/ > college), maternal health insurance sta-
tus (private or HMO or self-pay/public), maternal to-
bacco use during pregnancy (yes/no), alcohol use during
pregnancy (yes/no), parity (nulliparous/parous), previous
preeclampsia diagnosis (yes/no), gestational diabetes
(yes/no), use of assisted reproductive technology (ART;
yes/no), chronic hypertension (yes/no), self-reported use
of multivitamins (yes/no), calcium supplements (yes/no)
and iron supplements (yes/no) during pregnancy, and
infant sex (male/female) (Additional file 1: Figure S2).
Factors were retained in adjusted analyses if their inclu-
sion influenced effect estimates by > 10%. As a second-
ary analysis, we recreated the same statistical models
excluding BMI as a covariate because of its potential role
as a collider [39].
Fourth, the relationships between urinary trace metals
and maternal angiogenic biomarkers were assessed using
linear regression models. Trace metal species were log-
transformed to improve model fit (i.e. lower AIC) and
maternal angiogenic biomarkers were log-transformed to
approximate a normal distribution. To ensure compar-
ability between analyses, crude and adjusted models
were constructed using the same confounders as the
Cox models. Given that both the exposure and the out-
come variables were log-transformed, beta estimates and
standard errors from these regression models were con-
verted to percent change (95% CI) associated with an
IQR increase in trace metals concentration for
interpretability.
Lastly, in addition to using single-contaminant
models, urinary trace metals were investigated as a
mixture using PCA. PCA was applied to the set of 13
urinary trace metals with > 30% detection to produce
principal components (PCs). Urine metals measures
were log-transformed and adjusted for SG prior to
performing PCA to ensure normality and take the
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effect of hydration on the correlation of urinary
metals into account. SG-correction was used to ac-
count for urine dilution using the following formula:
MetalSG =Metal[(1.015–1)/(SG-1)], where MetalSG is
the specific gravity-corrected metal concentration,
Metal is the raw urinary trace metal concentration,
1.015 is the median specific gravity of all participants,
and SG is the specific gravity level for the sample
[40]. A combination of the “Eigenvalue-one” method and
the Scree test was used to determine a meaningful set of
components. Additionally, PCs were only retained if at
least three trace metals loaded onto them with a factor
loading > 0.40. Varimax rotation was used to maximize
the variance in the factor pattern matrix [41]. While 13
urinary metals were initially included in PCA, Ba and Mo
loaded onto multiple components, indicating that they
were complex items [41]. Therefore, PCA was re-created
excluding these metals. These PCA scores were then fit to
[1] unadjusted and adjusted Cox proportional hazard
models to estimate the relationship between a 1-unit
change in PC score and the HR of preeclampsia, and [2]
unadjusted and adjusted linear regression models to
estimate the relationship between a 1-unit change in PC
score and the percent change in circulating angiogenic
biomarkers. Given that PCA revealed components loaded
by toxic and essential metals, we examined interactions
between groups of toxic and essential metals using nested
interaction and main effects models. Significant inter-
actions were identified using a likelihood ratio test (LRT).
Interactions were considered significant if the LRT p-value
< 0.10. For these models, the PC loaded by essential
metals was dichotomized at the median (< median vs. >
median) in order to report the association between toxic
metals and preeclampsia among individuals with low vs.
high levels of essential metals.
All analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC, USA). Unless otherwise stated,
significance was defined as p-value < 0.05.
Results
Subject demographics and urinary metals
Study sample demographics are summarized in Table 1.
Briefly, the weighted study population had a median age
of 32.7 years, a pre-pregnancy BMI of 23.9 kg/m2, was
predominantly White (60.3%), and well-educated (86.5%
postsecondary education). Women who developed
preeclampsia were more likely to have a higher pre-
pregnancy BMI (29.3 vs 23.8 kg/m2; p < 0.01), have been
diagnosed with preeclampsia in a previous pregnancy
(8.3% vs. 2.3%; p = 0.03), have used ART to become
pregnant (24.3% vs. 8.3%; p = 0.02), have chronic hyper-
tension (12.5% vs. 2.3%; p < 0.01), and be carrying a
female fetus (77.2% vs. 42.8% male; p < 0.01). Women
who developed preeclampsia were also more likely to
report using calcium supplements during pregnancy (27.1%
vs. 13.3%; p = 0.07) compared to women who did not. With
respect to angiogenic biomarkers, circulating levels of PlGF
were lower (275 vs. 456 pg/mL; p < 0.01) and the sFlt-1/
PlGF ratio was higher (23.2 vs. 13.3; p = 0.04) among
women who developed preeclampsia compared to those
that did not. Interestingly, although previous analyses in the
LIFECODES cohort have demonstrated differences in the
trajectory of sFlt-1 levels between preeclamptics and non-
preeclamptics throughout pregnancy [42], circulating sFlt-1
levels at the 3rd study visit did not differ by preeclampsia
status.
Medians (IQRs) of SG-adjusted trace metals in 3rd
study visit urine samples by preeclampsia status are
shown in Table 2. Most trace metals had high detection
rates. However, Be, Cr, U, and W were detected in < 30%
of the samples. These metals were treated as detect vs.
non-detect in all subsequent analyses. Overall, the distri-
bution of metals in the urine was similar in women who
developed preeclampsia and women who did not.
Urinary trace metals and preeclampsia risk
After adjusting for smoking during pregnancy, mater-
nal race, maternal educational attainment, insurance
status, infant sex, ART use, self-reported calcium sup-
plementation, and pre-pregnancy BMI, the detection
of Cr in urine was positively associated with pre-
eclampsia risk (HR: 3.48, 95% CI: 1.02, 11.8) (Table 3).
This association was similar in models excluding BMI
(see Additional file 1: Table S1). However, it should
be noted that Cr was only detected in 15% (N = 57)
of all participants and 22% (N = 7) of the women who
developed preeclampsia and this association is based
on a limited number of observations. In addition, an
IQR-increase in urinary Se was associated with a re-
duction in the risk of preeclampsia (HR: 0.28, 95%
CI: 0.08, 0.94).
Urinary trace metals and circulating maternal angiogenic
biomarkers
After adjusting for potential confounders, urinary Cu was
associated with higher circulating sFlt-1 levels (% Change:
11.5, 95% CI: 0.18, 24.1) (Table 4). No other statistically
significant associations were observed between urinary
metals and sFlt-1 levels. Several metals were associated with
lower levels of circulating PlGF. Namely, an IQR-increase
in urinary Cd (% Change: -6.99, 95% CI: − 13.1, − 0.47),
urinary Pb (% Change: -7.20, 95% CI: − 11.8, − 2.33), and
detection of urinary Cr (% Change: -24.5, 95% CI: − 38.2, −
7.77) was associated with lower levels of circulating PlGF.
In addition, urinary Cu and Se were also associated
with lower circulating PlGF levels. Urinary Cu was also
associated with a 23.7% (95% CI: 6.44, 43.8) higher sFlt-
1/PlGF ratio (Table 4). Results from crude models and
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Table 1 Weighted LIFECODES demographic characteristics overall and by preeclampsia status: crude N (weighted %) or weighted
median (weighted IQR)
Overall (N = 383) Preeclamptic (N = 28) Non-Preeclamptic (N = 355) P*
Maternal Age (years) 32.7 (29.1, 35.7) 33.0 (29.0, 35.1) 32.7 (29.1, 35.7) 0.62
Pre-pregnancy BMI (kg/m2)a 23.9 (21.4, 27.9) 29.8 (24.5, 36.7) 23.8 (21.3, 27.4) < 0.01
Maternal Race
White 231 (60.3%) 21 (75.0%) 210 (59.2%) 0.11
African American 57 (14.9%) 6 (19.4%) 51 (14.8%)
Other 95 (24.8%) 1 (5.6%) 94 (26.1%)
Maternal Educationa
< High School 53 (13.6%) 7 (21.5%) 46 (13.1%) 0.39
Technical College 57 (14.9%) 3 (9.7%) 54 (15.2%)
Junior College or Some College 115 (31.3%) 11 (40.3%) 104 (30.7%)
> College 148 (40.3%) 7 (28.5%) 141 (41.0%)
Maternal Health Insuranceb
Private/HMO/Self-Pay 311 (82.7%) 25 (90.3%) 286 (82.2%) 0.31
Public 63 (17.3%) 3 (9.7%) 60 (17.8%)
Maternal Smoking During Pregnancyc
No 353 (93.9%) 24 (91.7%) 329 (94.0%) 0.56
Yes 25 (6.1%) 4 (8.3%) 21 (6.0%)
Maternal Alcohol Use During Pregnancyb
No 359 (95.2%) 28 (100.0%) 331 (94.9%)
Yes 15 (4.8%) 0 (0.0%) 15 (5.1%)
Parity
Nulliparous 167 (43.8%) 12 (42.4%) 155 (43.9%) 0.88
Parous 216 (56.2%) 16 (57.6%) 200 (56.1%)
Previous Preeclampsia Diagnosis
No 370 (97.3%) 24 (91.7%) 346 (97.7%) 0.03
Yes 13 (2.7%) 4 (8.3%) 9 (2.3%)
Gestational Diabetes
No 355 (93.4%) 25 (90.3%) 330 (93.6%) 0.52
Yes 28 (6.6%) 3 (9.7%) 25 (6.4%)
Use of ART
No 349 (90.8%) 23 (75.7%) 326 (91.7%) 0.02
Yes 34 (9.2%) 5 (24.3%) 29 (8.3%)
Chronic Hypertension
No 368 (97.1%) 22 (87.6%) 346 (97.7%) < 0.01
Yes 15 (2.9%) 6 (12.5%) 9 (2.3%)
Use of Multivitamins During Pregnancyc
No 106 (27.4%) 8 (30.6%) 98 (27.2%) 0.73
Yes 272 (72.6%) 20 (69.4%) 252 (72.8%)
Use of Calcium Supplements During Pregnancyc
No 324 (85.9%) 20 (72.9%) 304 (86.7%) 0.07
Yes 54 (14.1%) 8 (27.1%) 46 (13.3%)
Use of Iron Supplement During Pregnancyc
No 336 (88.7%) 24 (91.7%) 312 (88.5%) 0.53
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models excluding BMI remained highly similar (see
Additional file 1: Table S2).
Trace metals mixtures, preeclampsia risk, and Angiogenic
biomarkers
Using PCA, we identified three primary PCs, which ex-
plained 46.0% of the variance in urinary metals. PC1 was
characterized by higher loading of essential metals (Cu,
Se, and Zn); PC2 was characterized by higher loading of
toxic metals (As, Mn, and Pb); and PC3 was characterized
by higher loading of seafood-associated metals (As, Hg,
and Sn) [43–45]. These factor loading patterns have been
previously observed in our examination of urinary trace
metals and preterm birth in this study population [32].
Factor loadings and communalities for urinary metals are
displayed in (see Additional file 1: Table S3).
With respect to preeclampsia, neither PC1 (Cu, Se, and
Zn) (HR: 0.89, 95% CI: 0.35, 2.29), PC2 (Cd, Mn, and Pb)
(HR: 1.63, 95% CI: 0.74, 3.61), nor PC3 (As, Hg, and Sn)
(HR: 0.75, 95% CI: 0.39, 1.46) were statistically signifi-
cantly associated with preeclampsia (Table 3). Interactions
between PCs loaded by toxic/seafood-associated metals
(i.e. PC2 and PC3) and PCs loaded by essential metals
(PC1) were further investigated (Fig. 1). While there was
Table 1 Weighted LIFECODES demographic characteristics overall and by preeclampsia status: crude N (weighted %) or weighted
median (weighted IQR) (Continued)
Overall (N = 383) Preeclamptic (N = 28) Non-Preeclamptic (N = 355) P*
Yes 42 (11.3%) 4 (8.3%) 38 (11.5%)
Infant Sex
Female 166 (44.7%) 17 (77.2%) 149 (42.8%) < 0.01
Male 217 (55.3%) 11 (22.8%) 206 (57.2%)
Maternal sFlt-1Expressiond (ng/mL) 5.79 (3.85, 9.12) 6.30 (4.15, 9.88) 5.72 (3.83, 9.06) 0.29
Maternal PLGF Expressione (pg/mL) 448 (284, 645) 275 (421, 132) 456 (292, 651) < 0.01
Maternal sFlt-1/PLGF Ratiod 13.8 (8.27, 22.9) 23.2 (12.0, 39.9) 13.3 (8.11, 22.3) 0.03
Abbreviations: IQR interquartile range, BMI body mass index, ART assisted reproductive technology, sFlt-1 soluble fms-like tyrosine kinase-1, PlGF placental
growth factor
*p-value for weighted t-test, Chi-square test, or Fisher Exact test, where appropriate
a = 10 missing, b = 9 missing, c = 5 missing, d = 16 missing, e = 15 missing
Table 2 Weighted distribution of specific gravity-adjusted trace metals from 3rd study visit urine samples (μg/L) by preeclampsia
case status (N = 383)
Metals LOD N (%)
< LOD
Preeclamptic Median (IQR) or
N detected (weighted %)
Non-preeclamptic Median (IQR) or
N detected (weighted %)
As 0.30 0 (0) 15.9 (6.05, 21.7) 17.9 (9.59, 32.6)
Ba 0.10 4 (1.03) 2.25 (0.93, 4.11) 1.93 (0.98, 3.34)
Cd 0.06 214 (55.9) 0.09 (0.06, 0.14) 0.08 (0.04, 0.14)
Cu 2.50 32 (8.21) 9.62 (8.77, 11.7) 8.96 (6.73, 12.1)
Hg 0.05 32 (8.21) 0.50 (0.24, 0.76) 0.51 (0.27, 0.97)
Mn 0.08 6 (1.54) 0.91 (0.53, 1.18) 0.73 (0.51, 1.13)
Mo 0.30 0 (0) 45.6 (36.2, 69.6) 51.3 (37.1, 68.8)
Ni 0.80 54 (13.8) 3.40 (1.86, 3.97) 2.84 (1.88, 3.97)
Pb 0.10 92 (23.6) 0.34 (0.16, 0.64) 0.35 (0.15, 0.62)
Se 5.00 3 (0.08) 36.3 (31.2, 46.0) 37.0 (29.6, 45.6)
Sn 0.10 24 (6.15) 0.47 (0.28, 0.98) 0.63 (0.35, 1.22)
Tl 0.02 61 (15.6) 0.13 (0.09, 0.16) 0.13 (0.08, 0.18)
Zn 2.00 0 (0) 294 (206, 398) 242 (146, 364)
Bea 0.04 356 (91.3) 3 (9.72) 31 (9.61)
Cra 0.40 330 (84.6) 7 (21.5) 50 (13.2)
Ua 0.01 342 (87.7) 4 (15.3) 43 (11.3)
Wa 0.20 309 (79.2) 4 (15.3) 73 (19.5)
Abbreviations: LOD limit of detection, IQR interquartile range, As arsenic, Ba barium, Cd cadmium, Cu copper, Hg mercury, Mn manganese, Mo molybdenum, Ni
nickel, Pb lead, Se selenium, Sn tin, Tl thallium, Zn zinc, Be beryllium, Cr chromium, U uranium, W tungsten
aDenotes metals with > 70% of samples below the limit of detection
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no statistically significant interaction between PC1 (Cu,
Se, and Zn) and PC2 (Cd, Mn, and Pb) (pLRT = 0.12), the
association between PC2 (Cd, Mn, and Pb) and pre-
eclampsia (HR: 3.54, 95% CI: 1.09, 11.5) was significant
among individuals with low levels of PC1 (Cu, Se, and
Zn). On the other hand, this association was null among
individuals with higher levels of PC1(Cu, Se, and Zn).
After adjusting for potential confounders, PC1 (Cu, Se,
and Zn) (% Change: -13.5, 95% CI: − 22.6, − 3.41) and PC2
(Cd, Mn, and Pb) (% Change: -11.9, 95% CI: -20.7, -2.12)
were associated with lower circulating PlGF levels
(Table 4). The associations between PCs and angiogenic
biomarkers were similar in both crude and adjusted models
with BMI excluded (see Additional file 1: Table S2).
Discussion
In this study, the relationships between 17 trace urinary
metals, preeclampsia risk, and levels of maternal
circulating angiogenic biomarkers were investigated using
both a single-contaminant and mixtures-based approach.
In our single-contaminant approach, we observed an
increased risk of preeclampsia associated with the detec-
tion of Cr in the urine and a reduced risk of preeclampsia
associated with an IQR-increase in urinary Se. Urinary Cd,
along with other toxic and essential metals, was also asso-
ciated with reductions in circulating PlGF levels and uri-
nary Cu was associated with higher sFlt-1 levels and a
higher sFlt-1/PlGF ratio, suggesting an association with
impaired placentation and preeclampsia risk. In our
mixtures approach, we used PCA to further investigate
how combinations of urinary metals were associated with
the risk of preeclampsia and circulating angiogenic bio-
marker levels. Individual PCs were not associated with
preeclampsia risk, but both PC1 (Cu, Se, and Zn) and PC2
(Cd, Mn, and Pb) were associated with lower levels of
circulating PlGF. In addition, while we did not observe
a statistically significant interaction between PC1 (Cu,
Se, and Zn) and PC2 (Cd, Mn, and Pb), the asso-
ciation between PC2 (Cd, Mn, and Pb) and pre-
eclampsia was significant among individuals with low
levels of PC1 (Cu, Se, and Zn).
In single-contaminant models, detection of Cr in the
urine was associated with an increased risk of preeclamp-
sia and a reduction in circulating PlGF levels, suggesting
that Cr is associated with a reduction in placentation and
placental function. While the effect estimates were rela-
tively imprecise, other studies have also noted higher
levels of total urinary or hair Cr in preeclampsia cases
compared to normotensive controls [11, 15]. Urinary Cr
levels in this cohort were low, with most samples being
below the LOD, but the primary source of exposure to Cr
in the general population is from food, particularly from
meat and fish products [46]. Recent toxicologic studies
have also demonstrated that hexavalent Cr exposure leads
to increased expression of oxidative stress markers and
apoptotic signaling in trophoblast cells and mouse
placenta [47–49], providing further molecular-level evi-
dence for a potential link between Cr exposure and pre-
eclampsia. Despite the consistency of association between
urinary Cr, angiogenic biomarkers, and preeclampsia, we
did not feel that it was appropriate to apply mediation
analysis methodologies to this cohort given the small
number of samples with Cr above the LOD, the relatively
high degree of imprecision in the estimates, and the lack
of clear connection between Cr exposure and
preeclampsia in current epidemiologic and toxicologic
literature. Nevertheless, we feel that these results warrant
further research.
Although we did not find associations between other
toxic metals and the risk of preeclampsia, we identified
associations between urinary Cd and Pb and lower circu-
lating PlGF levels. These results may provide additional
Table 3 Adjusteda association between urinary metals and the
HR (95% CI) of preeclampsia
Adjusteda HR (95% CI) p
Single Contaminant Models
As 0.73 (0.46, 1.16) 0.18
Ba 1.05 (0.62, 1.79) 0.85
Cd 0.94 (0.54, 1.64) 0.83
Cu 0.71 (0.23, 2.24) 0.56
Hg 0.90 (0.63, 1.28) 0.55
Mn 1.26 (0.75, 2.12) 0.39
Mo 0.47 (0.21, 1.04) 0.06
Ni 0.89 (0.50, 1.59) 0.69
Pb 0.97 (0.67, 1.40) 0.86
Se 0.28 (0.08, 0.94) 0.04
Sn 0.82 (0.48, 1.38) 0.45
Tl 0.80 (0.47, 1.37) 0.42
Zn 0.94 (0.44, 2.02) 0.88
Beb 1.46 (0.32, 6.74) 0.63
Crb 3.48 (1.02, 11.8) 0.05
Ub 0.99 (0.23, 4.21) 0.99
Wb 1.77 (0.49, 6.37) 0.38
Principal Components Analysis Models
PC1: Cu, Se, and Zn 0.89 (0.35, 2.29) 0.81
PC2: Cd, Mn, and Pb 1.63 (0.74, 3.61) 0.22
PC3: As, Hg, and Sn 0.75 (0.39, 1.46) 0.40
Abbreviations: HR hazard ratio, CI confidence interval, PC principal component,
As arsenic, Ba barium, Cd cadmium, Cu copper, Hg mercury, Mn manganese,
Mo molybdenum, Ni nickel, Pb lead, Se selenium, Sn tin, Tl thallium, Zn zinc, Be
beryllium, Cr chromium, U uranium, W tungsten
aAdjusted for specific gravity (for continuously measured metals in single-
contaminant models), smoking during pregnancy, race, educational
attainment, insurance status, infant sex, ART, calcium supplementation, pre-
pregnancy BMI, and gestational age at study visit
bDenotes metals with > 70% of samples below the limit of detection
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Table 4 Adjusteda relationship between urinary trace metals and the percent change (95% CI) in circulating maternal angiogenic
biomarkers
sFlt-1 PlGF sFlt-1/PlGF Ratio
% Change (95% CI) p % Change (95% CI) p % Change (95% CI) p
Single Contaminant Models
As −0.88 (−7.07, 5.73) 0.79 0.05 (− 6.47, 7.03) 1.0 −1.96 (− 10.5, 7.39) 0.67
Ba −0.95 (−7.24, 5.78) 0.78 −2.77 (− 9.23, 4.15) 0.42 2.06 (− 6.99, 12.0) 0.67
Cd −0.45 (−6.72, 6.24) 0.89 −6.99 (− 13.1, − 0.47) 0.04 6.64 (− 2.71, 16.9) 0.17
Cu 11.5 (0.18, 24.1) 0.05 −10.6 (− 20.1, − 0.001) 0.05 23.7 (6.44, 43.8) < 0.01
Hg 4.99 (−0.95, 11.3) 0.10 −1.65 (−7.48, 4.56) 0.59 6.17 (−2.22, 15.3) 0.15
Mn 1.45 (−5.89, 9.36) 0.71 −1.44 (−8.89, 6.62) 0.72 1.88 (−8.37, 13.3) 0.73
Mo 0.69 (−9.49, 12.0) 0.90 4.99 (−6.09, 17.4) 0.39 −5.72 (−18.9, 9.60) 0.44
Ni 2.27 (−6.46, 11.8) 0.62 −0.51 (−9.39, 9.24) 0.92 4.22 (− 8.12, 18.2) 0.52
Pb −2.34 (−7.03, 2.58) 0.35 −7.20 (−11.8, − 2.33) < 0.01 4.80 (− 2.24, 12.4) 0.19
Se −4.07 (− 19.5, 14.3) 0.64 − 18.2 (−31.8, − 1.80) 0.03 15.9 (− 9.49, 48.3) 0.24
Sn 5.15 (− 1.17, 11.9) 0.11 4.98 (− 1.61, 12.0) 0.14 0.22 (− 8.20, 9.42) 0.96
Tl −4.52 (−11.1, 2.56) 0.20 −4.35 (− 11.3, 3.08) 0.24 −0.30 (− 9.89, 10.3) 0.95
Zn −2.67 (−11.22, 6.7) 0.56 −5.17 (− 13.9, 4.41) 0.28 3.45 (−9.16, 17.8) 0.61
Beb −6.72 (−25.2, 16.3) 0.54 15.3 (−8.42, 45.2) 0.23 −17.5 (−39.5, 12.6) 0.23
Crb −9.09 (−25.4, 10.8) 0.34 −24.5 (−38.2, − 7.77) < 0.01 5.25 (− 20.4, 39.1) 0.72
Ub −17.7 (− 33.3, 1.48) 0.07 − 9.16 (− 27.1, 13.1) 0.39 −11.1 (− 33.9, 19.5) 0.44
Wb 1.09 (−14.0, 18.9) 0.90 −1.62 (− 16.9, 16.5) 0.85 4.77 (− 16.6, 31.7) 0.69
Principal Components Analysis
PC1: Cu, Se, and Zn −3.85 (−13.7, 7.07) 0.47 −13.5 (−22.6, − 3.41) 0.01 11.6 (− 3.97, 29.8) 0.15
PC2: Cd, Mn, and Pb 2.23 (−7.74, 13.3) 0.67 −11.9 (−20.7, − 2.12) 0.02 14.9 (−0.49, 32.8) 0.06
PC3: As, Hg, and Sn 4.59 (−5.71, 16.0) 0.40 3.43 (−7.03, 15.1) 0.54 0.56 (−13.0, 16.2) 0.94
Abbreviations: sFlt-1 soluble fms-like tyrosine, PlGF placental growth factor, HR hazard ratio, CI confidence interval, PC principal component, As arsenic, Ba barium,
Cd cadmium Cu copper, Hg mercury, Mn manganese, Mo molybdenum, Ni nickel, Pb lead, Se selenium, Sn tin, Tl thallium, Zn zinc, Be beryllium, Cr chromium, U
uranium, W tungsten
aAdjusted for specific gravity (for continuously measured metals in single-contaminant models), smoking during pregnancy, race, educational attainment,
insurance status, infant sex, ART, calcium supplementation, pre-pregnancy BMI, and gestational age at study visit
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Low Essential Metals (PC1)
High Essential Metals (PC1)
pLRT = 0.79
Fig. 1 Adjusteda HR (95% CI) of preeclampsia with PCs loaded by toxic metals (PC2) and seafood-associated metals (PC3) within strata of above
vs. below median levels of essential metals (PC1) aAdjusted for smoking during pregnancy, race, educational attainment, insurance status, infant
sex, ART, calcium supplementation, pre-pregnancy BMI, and gestational age at study visit. Abbreviations: HR, hazard ratio; CI, confidence interval,
PC, principal component, pLRT, likelihood ratio test p-value
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mechanistic evidence for previous studies that have re-
ported associations between prenatal Cd and Pb expo-
sure and preeclampsia [10, 13, 50]. Both Cd and Pb are
ubiquitous environmental exposures. Both may be found
in contaminated air, soil, or water. Cd levels tend to be
higher in certain foods, such as rice and grains, and both
Cd and Pb can be found in drinking water systems or
housing, particularly in areas with old or failing infra-
structure [51–53]. Similarly, the PC loaded by toxic
metals (PC2: Cd, Pb, and Mn) was not associated with
preeclampsia risk, but was associated with lower circu-
lating PlGF levels.
With respect to essential metals, we observed a reduc-
tion, albeit imprecise, in the risk of preeclampsia associ-
ated with an increase in urinary Se. This observation is
consistent with the literature, which suggests that essen-
tial metals, including Se, may reduce the risk of pre-
eclampsia [16, 17]. In contrast, urinary Cu and Se were
associated with lower circulating PlGF levels. Urinary Cu
was also associated with higher sFlt-1 and the sFlt-1/
PlGF ratio. Likewise, in our mixtures-based approach,
the PC for essential metals (PC1: Cu, Se, and Zn) was
associated with lower circulating PlGF levels. These find-
ings may suggest that, instead of having a beneficial
effect, levels of essential metals are associated with im-
paired placental angiogenesis and placentation. This is
consistent with previously observed associations between
urinary Cu and the risk of preterm birth, specifically
placentally-mediated preterm birth, in this study popula-
tion [32]. In addition, recent meta-analyses have re-
ported consistent observations that higher plasma or
serum Cu is associated with preeclampsia risk [54, 55].
While Cu is an integral component of the antioxidant
system, modest increases in Cu may lead to the produc-
tion of reactive oxygen species and oxidative stress,
which has been linked to the development of preeclamp-
sia [9, 56]. Alternatively, it has been suggested that
higher levels of essential metals, including Cu, may be
the result of preeclampsia, where women developing
preeclampsia may increase the uptake of essential metals
in attempt to buffer the higher levels oxidative stress
associated with the disease [56].
In addition to PC1 (Cu, Se, and Zn) and PC2 (Cd, Mn,
and Pb), we identified a third PC that was characterized
by loading from seafood-associated metals (PC3: As, Hg,
and Sn). Notably, while inorganic As is considered a
toxic metal, non-toxic organic forms of As, such as
arsenobetaine, are widely found in seafood [57]. In popu-
lations with frequent seafood consumption, including
those within the United States, much of the total urinary
As may be organic arsenicals from such foods [58–60].
In addition, although seafood-associated metals (PC3:
As, Hg, and Sn) grouped independently of other toxic
metals (PC2: Cd, Mn, and Pb), they should not be
considered non-toxic. For instance, pregnant women are
advised against consuming certain types of seafood on
the basis that it may contain high levels of methylmer-
cury [61]. Despite this, we did not identify associations
between PC3 (As, Hg, and Sn) and either preeclampsia
or angiogenic biomarkers. Disentangling the harmful ef-
fects of these trace metals from the beneficial effects of
seafood consumption (i.e. fatty acids) is complex and be-
yond the scope of this analysis.
Given known toxicologic interactions between toxic
and essential metals, we investigated statistical interac-
tions between toxic and essential metals with respect to
both preeclampsia risk and levels of circulating angio-
genic biomarkers. While there was no significant inter-
action between PC1 (Cu, Se, and Zn) and PC2 (Cd, Mn,
and Pb), the association between PC2 (Cd, Mn, and Pb)
and preeclampsia was significant among individuals with
lower levels of PC1 (Cu, Se, and Zn). Previously, signifi-
cant interactions between placental Cd and Se levels
were reported in a case-control study of preeclampsia
[10]. At a molecular level, these findings are supported
by evidence of toxic and essential metals interactions
within the placenta. For example, antagonistic interac-
tions between maternal toenail Cd and Se levels have
been noted with respect to placental apoptotic gene ex-
pression [29]. Taken together, these results may suggest
that individuals with low levels of essential metals may
be more susceptible to the effects of toxic exposures on
placental development and/or functioning.
This study has several strengths. First, the LIFECODES
birth cohort has a prospective study design. Urine sam-
ples were collected at the 3rd study visit and no patients
had developed preeclampsia at the time of sample col-
lection, reducing the likelihood that these results were
influenced by reverse causality. Nevertheless, it is pos-
sible that preeclampsia was subclinical at the time of
sample collection (median, 26 weeks gestation) because
the origins of preeclampsia may lie in the early stages of
pregnancy. Second, this study is among the first to em-
ploy a mixtures approach in the context of preeclampsia.
This is of critical importance given that populations are
exposed to complex mixtures of toxicants, rather than
single-contaminants, and represents a major public
health research objective [62].
Despite these strengths, this study also has several
limitations. First, this study had a small number of pre-
eclampsia cases. Thus, it was not possible to examine
the relationship between urinary metals and individual
subtypes of preeclampsia (i.e., early- vs. late-onset).
There is evidence that these subtypes may have different
underlying etiologies [63]. It should also be noted that
the sampling design of the case-control study that this
analysis is based in may have resulted in an over-
sampling of early-onset preeclampsia. However, this
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oversampling should be partially accounted for by the
inverse weighting approach used to account for selection
into the study on preterm birth status. In addition, the
limited sample size precluded an investigation of different
dose-response shapes for trace metals and preeclampsia.
Some, such as Mn, may feature non-monotonic dose-
response curves that are not well captured by linear
modeling. Second, with respect to exposure assessment,
biomarkers of exposure were only available as urinary
measures and at a single timepoint. Exposure to some
metals may be better captured using other matrices,
such as blood biomarkers for Se, Mn, Zn or Pb expo-
sure [64–67]. Moreover, multiple metals measures
taken throughout pregnancy would have allowed for a
better characterization of metals exposure throughout
pregnancy. In particular, metals measures taken earlier
during pregnancy may better capture exposure at the
time of early preeclampsia development. Third, we used
PCA as a mixtures-based approach to examine urinary
trace metals and preeclampsia. Like all statistical
methods for examining chemical mixtures, PCA has
limitations [68]. Unsupervised PCA reduces dimension-
ality by selecting linear combinations of variables with-
out considering how they relate to the outcome of
interest. Thus, while it identifies chemicals with similar
exposure patterns, it may not have selected the most
relevant groups of trace metals for preeclampsia or an-
giogenic biomarkers. Moreover, because exposure pat-
terns vary across populations, the PCs identified in this
study may not be generalizable to other studies. In
addition, by assuming linear combinations of variables
within a PC, it assumes no interactions between metals
within each cluster. Lastly, the generalizability of this
study may be limited given that participants were re-
cruited from BWH, a tertiary care center, which re-
ceives higher-risk pregnancies than other hospitals.
However, this population does exhibit similar concen-
trations of urinary trace metals to those observed in the
general United States population [32].
Conclusions
This study investigated 17 urinary metals, individually
and in mixtures, in association with circulating maternal
angiogenic biomarkers and preeclampsia. This study is
among the first to examine the relationship between pre-
natal trace metals exposure and maternal angiogenic
biomarkers, as well as the relationship between metals
mixtures and preeclampsia. The results from both our
single-contaminant and mixtures-based approach sug-
gests that both toxic and essential urinary metals are as-
sociated with adverse maternal profiles of angiogenic
biomarkers. In addition, there may be important interac-
tions between toxic and essential metals in the context
of preeclampsia.
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